natgillin/translations-raw huggingface dataset:
I intravenøse infusionsstudier blev renal tolerabilitet overfor zoledronsyre bestemt hos rotter, som fik 0,6 mg/kg givet som 15 minutters infusion i alt seks gange med 3 dages interval (for en kumulativ dosis svarende til AUC niveau cirka 6 gange højere den humane terapeutiske eksponering), mens fem 15 minutters infusioner af 0,25 mg/kg blev administreret med 2–3 ugers interval (en kumulativ dosis svarende til 7 gange den humane terapeutiske eksponering) hos hunde var fint tolereret.
In the intravenous infusion studies, renal tolerability of zoledronic acid was established in rats when given 0.6 mg/kg as 15-minute infusions at 3-day intervals, six times in total (for a cumulative dose that corresponded to AUC levels about 6 times the human therapeutic exposure) while five 15-minute infusions of 0.25 mg/kg administered at 2–3-week intervals (a cumulative dose that corresponded to 7 times the human therapeutic exposure) were well tolerated in dogs.
I intravenøse infusionsstudier fik raske mandlige frivillige ziconotid ved doser på op til 70.000 μg/dag eller 3.200 gange den maksimalt anbefalede daglige intratekale infusionsdosis.
In intravenous infusion studies, healthy male volunteers received ziconotide at doses of up to70,000 μg/day or 3,200 times the maximum recommended daily intrathecal infusion dose.
I IntronA (3 MIE 3 gange om ugen)
I IntronA (3 MIU 3 times a week)
I ipilimumab 3 mg/kg monoterapigruppen var den mediane OS 22 måneder og 8 måneder for patienter med henholdsvis SD og PD.
In the ipilimumab 3 mg/kg monotherapy group, median OS was 22 months and 8 months for patients with SD and those with PD, respectively.
I ITT-populationen i en ublindet dosisresponsundersøgelse, DPM-CF-202, var middelværdien (SD) for den procentvise ændring i FEV1 for dosen på 400 mg 8,75 (SD: 12,4) og -1,569 (SD: 9,0) for dosen på 40 mg (p < 0,0001).
In the ITT population of an open label dose response study, DPM-CF-202, the mean (SD) percent change in FEV1 for the 400 mg dose was 8.75 (SD: 12.4) and -1.569 (SD: 9.0) for 40 mg dose (p < 0.0001).
I ITT-populationen i studie MCL-002 var der samlet en tilsyneladende stigning i antal dødsfald inden for 20 uger med 22/170 (13 %) i lenalidomidarmen versus 6/84 (7 %) i kontrolarmen.
In study MCL-002 in the ITT population, there was an overall apparent increase in deaths within 20 weeks in the lenalidomide arm 22/170 (13%) versus 6/84 (7%) in the control arm.
I ivabradin- gruppen blev 67 % af patienterne behandlet med 7,5 mg to gange dagligt.
In the ivabradine group, 67% of patients were treated with 7.5 mg twice a day.
I Kaiser Permanente undersøgelsen var effekten 87,5% (95% CI: 7, 99 over for bakteriæmisk pneumoni på grund af vaccine serotyper af S. pneumoniae.
In the Kaiser Permanente trial, efficacy was 87.5 % (95 % CI: 7, 99) against bacteraemic pneumonia due to vaccine serotypes of S. pneumoniae.
I kaninforsøg med bazedoxifen forekom der ved maternelle toksiske doser på  0,5 mg/kg/dag (1,5 gange den humane eksponering) abort og højere incidens af anomalier i hjerte (ventrikelseptum- defekt) og skeletsystem (forsinkelse i ossifikation, misdannelse eller skævhed i knogler primært i rygsøjle og kranium) hos fostrene.
In rabbit studies with bazedoxifene, abortion and an increased incidence of heart (ventricular septal defect) and skeletal system (ossification delays, misshapen or misaligned bones, primarily of the spine and skull) anomalies in the fetuses were present at maternally toxic dosages of  0.5 mg/kg/day (1.5 times the human exposure).
I kapselskallen: gelatine, titaniumdioxid (E171), indigocarmin (E132).
In the capsule shell: gelatin, titanium dioxide (E171), indigo carmine (E132).
I kapslen: mikrokrystallinsk cellulose, laktosemonohydrat (se punkt 2 under ”Cerdelga indeholder laktose”), hypromellose og glyceroldibehenat.
In the capsule: microcrystalline cellulose, lactose monohydrate (see section 2 under ‘Cerdelga contains lactose’), hypromellose and glycerol dibehenate.
I kapslens skal: gelatine, kaliumaluminiumsilikat (E555), titandioxid (E171), gul jernoxid (E172) og indigotin (E132).
In the capsule shell: gelatin, potassium aluminium silicate (E555), titanium dioxide (E171), yellow iron oxide (E172) and indigotine (E132).
I kapslerne: mikrokrystallinsk cellulose, methacrylsyre-ethylacrylat copolymer, hypromellose, talcum, triethylcitrat, natriumlaurilsulfat.
In the capsules: microcrystalline cellulose, methacrylic acid - ethyl acrylate copolymer, hypromellose, talc, triethyl citrate, sodium lauryl sulfate.
I karcino- genitetsstudiet med rotter blev der set celler med flere cellekerner i leveren i fravær af andre histo- patologiske ændringer.
Multinucleated cells were seen in the liver in the absence of other histopathological changes in the rat carcinogenicity study.
I karcinogenicitetsforsøg over lang tid med ranolazindoser på op til 50 mg/kg/dag (150 mg/m2/dag) hos mus og 150 mg/kg/dag (900 mg/m2/dag) hos rotter sås der ingen relevant stigning i forekomsten af tumor uanset type.
In long-term carcinogenicity studies at doses of ranolazine up to 50 mg/kg/day (150 mg/m2/day) in mice and 150 mg/kg/day (900 mg/m2/day) in rats, no relevant increases in the incidence of any tumour types were seen.
I karcinogenicitetsstudier, øger nevirapin hepatiske tumorer i rotter og mus.
In carcinogenicity studies, nevirapine induces hepatic tumours in rats and mice.
I karton: Lyofilisat: Hætteglas (glas); Solvens: Hætteglas (glas)
In cardboard boxes: Lyophilisate: vial (glass); Solvent: vial (glass)
I karton: Lyofilisat: Hætteglas (glas); Solvens: Hætteglas (PET)
In cardboard boxes: Lyophilisate: vial (glass); Solvent: vial (PET)
I kenneler med gentagne udbrud af kliniske tegn på Isospora infektion, bør man over en længere periode behandle alle kuld for at kontrollere og gradvist reducere infektionsniveauet.
In kennels with recurring outbreaks of clinical disease due to Isospora infection, each litter should be treated for an extended period of time in order to control, and gradually reduce, the level of infection.
I klinisk praksis er det observeret, at miglustat- inducerede gastrointestinale bivirkninger reagerer på individuelle kostændringer (for eksempel nedsat indtagelse af saccharose, lactose og andre kulhydrater), på indtagelse af Zavesca mellem måltiderne og/eller på lægemidler mod diarré, såsom loperamid.
In clinical practice, miglustat-induced gastrointestinal events have been observed to respond to individualised diet modification (for example reduction of sucrose, lactose and other carbohydrate intake), to taking Zavesca between meals, and/or to anti-diarrhoeal medicinal products such as loperamide.
I klinisk praksis har fuldsblods dalkoncentrationerne generelt ligget på 5-20 ng/ml hos nyretransplanterede patienter i den tidlige periode efter transplantationen og 5-15 ng/ml under efterfølgende vedligeholdelsesbehandling.
In clinical practice, whole blood trough levels have generally been in the range of 5-20 ng/mL in kidney transplant patients in the early post- transplant period, and 5-15 ng/mL during subsequent maintenance therapy.
I kliniske afprøvninger der involverede over 350 patienter er der ikke observeret induktion af human antimus antistof (HAMA) overfor antistof fragmenter, ej heller har der været nogen øgning af HAMA niveauet hos patienter med eksisterende HAMA.
In clinical trials involving over 350 patients, no induction of human anti-mouse antibody (HAMA) to antibody fragments has been observed nor has there been any elevation of HAMA levels in patients with pre-existing HAMA.
I kliniske afprøvninger er enkeltdoser på 1.0 mg af LeukoScan mærket med 900 ± 200 MBq 99 m Tc blevet givet til 11 patienter med forskellige typer infektion og der var ingen bivirkninger ved denne dosis.
In clinical trials, single doses of 1.0 mg of LeukoScan radiolabelled with 900 ± 200 MBq of 99mTc were administered to 11 patients with various types of infection and there were no adverse reactions at this dose.
I kliniske farmakologisk-undersøgelser med enkelt-indgift af tadalafil (5 til 20 mg) var eksponeringen for tadalafil (AUC) ca. fordoblet hos forsøgspersoner med mild (kreatinin-clearance 51 til 80 ml/min) eller moderat (kreatinin-clearance 31 til 50 ml/min) nyrefunktionsnedsættelse samt hos dialysepatienter med nyresvigt i slutstadie.
In clinical pharmacology studies using single-dose tadalafil (5 to 20 mg), tadalafil exposure (AUC) approximately doubled in subjects with mild (creatinine clearance 51 to 80 ml/min) or moderate (creatinine clearance 31 to 50 ml/min) renal impairment and in subjects with end-stage renal disease on dialysis.
I kliniske farmakologisk-undersøgelser med enkelt-indgift af tadalafil (5til 20 mg) var eksponeringen for tadalafil (AUC) ca. fordoblet hos forsøgspersoner med mild (kreatinin-clearance 51 til 80 ml/min) eller moderat (kreatinin-clearance 31 til 50 ml/min) nyrefunktionsnedsættelse samt hos dialyse- patienter med nyresvigt i slutstadie.
In clinical pharmacology studies using single-dose tadalafil (5 to 20 mg), tadalafil exposure (AUC) approximately doubled in subjects with mild (creatinine clearance 51 to 80 ml/min) or moderate (creatinine clearance 31 to 50 ml/min) renal impairment and in subjects with end-stage renal disease on dialysis.
I kliniske farmakologiske studier hos voksne gav samtidig indgift med alkohol ikke en øgning af den alkoholinducerede forringelse af præstationsevnen eller øget søvnighed.
In clinical pharmacology trials in adults, co-administration with alcohol did not increase the alcohol- induced impairment in performance or increase in sleepiness.
I kliniske farmakologistudier har intravenøst insulin glargin og human insulin vist sig at være ækvipotente, når disse blev givet i samme doser.
In a clinical pharmacology study, intravenous insulin glargine and human insulin have been shown to be equipotent when given at the same doses.
I kliniske farmakologistudier var halveringstiden af naloxegol i terapeutiske doser 6 til 11 timer.
In clinical pharmacology studies, the half-life of naloxegol at therapeutic dose ranged from 6–11 hours.
I kliniske fase 2/3-studier fik 2.473 patienter dalbavancin administreret enten som en enkelt infusion på 1.500 mg eller som 1.000 mg efterfulgt af 500 mg en uge senere.
In Phase 2 / 3 clinical studies, 2,473 patients received dalbavancin administered as either a single infusion of 1500 mg or as 1000 mg followed one week later by 500 mg.
I kliniske fase 3- studier med MF sås hverken CTCAE grad 3 eller 4 hyperkolesterolæmi eller forhøjet aspartataminotransferase eller CTCAE grad 4 forhøjet alaninaminotransferanse
In phase 3 clinical studies in MF, neither CTCAE grade 3 or 4 hypercholesterolaemia, raised aspartate aminotransferase nor CTCAE grade 4 raised alanine aminotransferase were observed.
I kliniske fase I- og II-studier med reslizumab 3 mg/kg blev der observeret en reduktion af eosinofiler i blodet efter den første dosis, hvilket blev opretholdt til og med behandlingsuge 52 uden nogen tegn på takyfylaksi.
In clinical Studies I and II with reslizumab 3 mg/kg, decreases in blood eosinophil counts were seen following the first dose and maintained through 52 weeks of treatment with no signs of tachyphylaxis.
I kliniske fase I/II-studier blev et begrænset antal patienter behandlet med daglige doser af Tagrisso på op til 240 mg uden dosisbegrænsende toksicitet.
In phase I/II clinical trials a limited number of patients were treated with TAGRISSO daily doses of up to 240 mg without dose limiting toxicities.
I kliniske fase II-studier med patienter med fremskreden malignitet med involvering af knogle medførte subkutan (s.c.) dosering af XGEVA enten hver 4. uge eller hver 12. uge en hurtig reduktion i markører for knogleresorption (uNTx/Cr, serum-CTx) med median reduktion indenfor en uge på cirka 80% for uNTx/Cr, uanset tidligere behandling med bisfosfonater eller uNTx/Cr-niveau ved baseline.
In phase II clinical studies of patients with advanced malignancies involving bone, subcutaneous (SC) dosing of XGEVA administered either every 4 weeks or every 12 weeks resulted in a rapid reduction in markers of bone resorption (uNTx/Cr, serum CTx), with median reductions of approximately 80% for uNTx/Cr occurring within 1 week regardless of prior bisphosphonate therapy or baseline uNTx/Cr level.
I kliniske fase III-studier blev i alt 384 patienter behandlet med Ameluz.
In clinical phase III, at total of 384 patients were treated with Ameluz.
I kliniske forsøg af monoterapi med oral topotecan til patienter med recidiverende småcellet lungecancer var den dosisbegrænsende toksicitet hæmatologisk.
In clinical trials involving patients with relapsed small cell lung cancer, the dose limiting toxicity of oral topotecan monotherapy was found to be haematological.
I kliniske forsøg applicerede kirurgen et tyndt lag Raplixa der typisk svarede til doser på 0,3 g til 2 g.
In clinical trials a thin layer of Raplixa produced doses that typically ranged from 0.3 to 2 g.
I kliniske forsøg blev 0,1 % af patienterne (7 ud af 4.846 patienter med primær hyperlipidæmi og blandet dyslipidæmi og 0 ud af 80 patienter med homozygot familiær hyperkolesterolæmi), der blev behandlet med mindst én dosis Repatha, testet positive for udvikling af bindende antistoffer (4 af disse patienter havde transiente antistoffer).
In clinical studies, 0.1% of patients (7 out of 4846 patients with primary hyperlipidaemia and mixed dyslipidaemia and 0 out of 80 patients with homozygous familial hypercholesterolaemia) treated with at least one dose of Repatha tested positive for binding antibody development (4 of these patients had transient antibodies).
I kliniske forsøg blev brugen af Nimenrix som booster efter primær vaccination med Nimenrix eller andre meningokokvacciner (firtetravalent, konjugeret meningokok A-, C-, W- og Y-DT-konjugeret vaccine eller monovalent gruppe C-konjugerede vacciner) blev bevalueret i kliniske forsøgstudier.
In clinical trials, the use of Nimenrix as a booster following primary vaccination with Nimenrix or other meningococcal vaccines (quadrivalent meningococcal A, C, W and Y-DT conjugate vaccine or monovalent group C conjugate vaccines) was evaluated.
I kliniske forsøg blev brugen af Nimenrix som booster efter primær vaccination med Nimenrix eller andre meningokokvacciner (tetravalent, konjugeret meningokok A-, C-, W- og Y-DT-konjugeret vaccine eller monovalent gruppe C-konjugerede vacciner) blev evalueret i kliniske forsøgstudier.
In clinical trials, the use of Nimenrix as a booster following primary vaccination with Nimenrix or other meningococcal vaccines (quadrivalent meningococcal A, C, W, and Y-DT conjugate vaccine or monovalent group C conjugate vaccines) was evaluated.
I kliniske forsøg blev der kun anvendt saltvand til ørerensning.
In clinical trials, saline only was used for ear cleaning.
I kliniske forsøg blev der observeret 2 tilfælde af anti-GBM-sygdom.
In clinical trials, there were 2 cases of anti-GBM disease.
I kliniske forsøg blev der på mindre blødende områder (< 10 cm2) i gennemsnit anvendt 0,5 til 1 g.
In clinical trials, smaller bleeding sites (< 10 cm2) used 0.5 g to 1 g on average.
I kliniske forsøg blev doser med elosulfase alfa på op til 4 mg/kg per uge undersøgt, og der blev ikke identificeret nogen specifikke tegn eller symptomer efter de høje doser.
In clinical trials, doses of elosulfase alfa were explored up to 4 mg/kg per week and no specific signs or symptoms were identified following the higher doses.
I kliniske forsøg blev følgende reaktioner rapporteret med en frekvensforskel på ≥ 1 % forskel i frekvensen i forhold til placebo: Kvalme, opkastning, smerter i ekstremiteter, svimmelhed, depression og dyspnø.
In clinical trials the following reactions were reported at a ≥ 1 % difference in frequency from placebo: vertigo, nausea, pain in limb, dizziness, depression, dyspnoea.
I kliniske forsøg blev immunrelateret colitis associeret med tegn på slimhindeinflammation, med eller uden ulceration, samt infiltration af lymfocytter og neutrofile granulocytter.
In clinical trials, immune-related colitis was associated with evidence of mucosal inflammation, with or without ulcerations, and lymphocytic and neutrophilic infiltration.
I kliniske forsøg blev mycophenolatmofetil anvendt til patienter, der ikke responderede på kortikosteroid–behandling, eller som havde forhøjede levertal under kortikosteroidnedtrapningen, og som ikke responderede på en øget dosis kortikosteroid (se produktresumeet for mycophenolatmofetil).
In clinical trials, mycophenolate mofetil was used in patients without response to corticosteroid therapy, or who had an LFT elevation during corticosteroid tapering that was not responsive to an increase in the dose of corticosteroids (see the Summary of Product Characteristics for mycophenolate mofetil).
I kliniske forsøg blev ONIVYDE indgivet i doser på op til 240 mg/m2 til patienter med forskellige former for cancer.
In clinical trials, ONIVYDE was administered at doses up to 240 mg/m2 to patients with various cancers.
I kliniske forsøg blev op til 3 % af de voksne patienter testet seropositive mindst én gang i løbet af undersøgelsen for antistoffer, som er i stand til at neutralisere de biologiske effekter af anakinra.
In clinical trials, up to 3% of adult patients tested seropositive at least once during the study for antibodies capable of neutralising the biologic effects of anakinra.
I kliniske forsøg blev patienter med alvorlig mangel på FSH og LH defineret ved et endogent serumniveau af LH < 1,2 IE/l målt i et centralt laboratorium.
In clinical trials, patients with severe FSH and LH deficiency were defined by an endogenous serum LH level < 1.2 IU/l as measured in a central laboratory.
I kliniske forsøg blev patienter med kreatinin-clearance (CrCl) > 60 ml/min inkluderet og behandlet med den anbefalede dosis.
In clinical studies, patients with CrCl (creatinine clearance)  60 mL/min were included and treated at the recommended dose.
I kliniske forsøg blev patienter præmedicineret med 1.000 mg methylprednisolon de første 3 dage i begge behandlingsforløb med LEMTRADA.
In clinical trials, patients were pre-treated with 1,000 mg methylprednisolone for the first 3 days of each LEMTRADA treatment course.
I kliniske forsøg blev SCC (spinal/cervical cord compression) observeret både hos patienter, der fik Vimizim og hos patienter, der fik placebo.
In clinical trials, spinal/cervical cord compression (SCC) was observed both in patients receiving Vimizim and patients receiving placebo.
I kliniske forsøg blev topotecan-behandlingen stoppet, hvis dosis var blevet reduceret til 1,5 mg/m2.
In clinical trials, topotecan was discontinued if the dose needed to be reduced below 1.5 mg/m2.
I kliniske forsøg blev topotecanbehandlingen seponeret, hvis dosis var blevet reduceret til 1,0 mg/m2 og yderligere reduktion af dosis var nødvendig for at håndtere bivirkninger.
In clinical trials, topotecan was discontinued if the dose had been reduced to 1.0 mg/m2 and a further dose reduction was required to manage adverse effects.
I kliniske forsøg brugte 60,2% af de kvinder på 16 til 26 år, som fik Gardasil 9, hormonelle præventionsmidler i de kliniske forsøgs vaccinationsperiode.
In clinical studies, 60.2% of women aged 16 through 26 years who received Gardasil 9 used hormonal contraceptives during the vaccination period of the clinical studies.
I kliniske forsøg er Circadin administreret i daglige doser på 5 mg over 12 måneder, og der er ikke observeret ændringer i arten af de registrerede bivirkninger.
Circadin has been administered at 5 mg daily doses in clinical trials over 12 months without significantly changing the nature of the adverse reactions reported.
I kliniske forsøg er Circadin blevet givet sammen med thioridazin og imipramin, aktive stoffer der påvirker centralnervesystemet.
Circadin has been co-administered in studies with thioridazine and imipramine, active substances which affect the central nervous system.
I kliniske forsøg er hyppigheden af synkope ”ikke almindelig”, og der er ingen forskel mellem de epilepsipatienter, der fik lacosamid (0,1 %), og de epilepsipatienter, der fik placebo (0,3 %).
In clinical trials, the incidence rate for syncope is uncommon and did not differ between lacosamide treated epilepsy patients (0.1%) and placebo treated epilepsy patients (0.3%).
I kliniske forsøg er interaktioner mellem Kineret og andre lægemidler (inklusiv non-steroide anti-inflammatorika, kortikosteroider og DMARDs) ikke observeret.
In clinical trials, interactions between Kineret and other medicinal products (including nonsteroidal anti-inflammatory medicinal products, corticosteroids, and DMARDs) have not been observed.
I kliniske forsøg er resistens over for delamanid defineret som enhver vækst i tilstedeværelsen af en delamanidkoncentration på 0,2 g/ml, der er større end 1 % af den, der findes i medicinfrie kontrolkulturer på Middlebrook 7H11-medie.
In clinical trials resistance to delamanid has been defined as any growth in the presence of a delamanid concentration of 0.2 μg/mL that is greater than 1% of that on drug-free control cultures on Middlebrook 7H11 medium.
I kliniske forsøg fik patienterne 200 mg aciclovir to gange om dagen eller behandling ækvivalent hermed.
In clinical trials patients were administered aciclovir 200 mg twice a day or equivalent.
I kliniske forsøg fik patienterne 200 mg aciclovir to gange om dagen eller behandling ækvivalent hermed.
In clinical trials, patients were administered aciclovir 200 mg twice a day or equivalent.
I kliniske forsøg havde en daglig dosis på 10-30 mg Aripiprazole ingen signifikant effekt på metabolismen af CYP2D6-substrater (dextromethorphan/3-methoxymorphinan forholdet), CYP2C9 (warfarin), CYP2C19 (omeprazol) og CYP3A4 (dextromethorphan).
In clinical studies, 10-30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
I kliniske forsøg havde en daglig oral dosis på 10-30 mg aripiprazol ingen signifikant effekt på metabolismen af CYP2D6-substrater (dextromethorphan/3-methoxymorphinan forholdet), CYP2C9 (warfarin), CYP2C19 (omeprazol) og CYP3A4 (dextromethorphan).
In clinical studies, oral doses of 10-30 mg/day of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
I kliniske forsøg havde maropitant plasmaniveauer effekt en time efter administration.
During clinical studies maropitant plasma levels conferred efficacy from 1 hour after administration.
I kliniske forsøg hos patienter med lægemiddelinduceret (dopaminagonist) psykose i relation til Parkinsons sygdom blev forværring af Parkinson symptomatologi og hallucinationer meget almindeligt rapporteret og hyppigere end for placebo.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.
I kliniske forsøg med 1.784 patienter i behandling med Axura for mild til svær demens og med 1.595 patienter i placebobehandling adskilte den generelle incidensrate for bivirkninger med Axura sig ikke fra placebobehandlingen, og bivirkningerne var som regel milde til moderate.
In clinical trials in mild to severe dementia, involving 1,784 patients treated with Axura and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with Axura did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity.
I kliniske forsøg med 1.784 patienter i behandling med Memantine Merz for mild til svær demens og med 1.595 patienter i placebobehandling adskilte den generelle incidensrate for bivirkninger med Memantine Merz sig ikke fra placebobehandlingen, og bivirkningerne var som regel milde til moderate.
In clinical trials in mild to severe dementia, involving 1,784 patients treated with Memantine Merz and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with Memantine Merz did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity.